hVIVO (LON:HVO – Get Free Report)‘s stock had its “buy” rating restated by Peel Hunt in a note issued to investors on Monday, Digital Look reports. They currently have a GBX 14 price objective on the stock. Peel Hunt’s price target indicates a potential upside of 140.96% from the company’s previous close.
hVIVO Stock Performance
HVO stock opened at GBX 5.81 on Monday. hVIVO has a one year low of GBX 4.30 and a one year high of GBX 11. The firm has a 50-day simple moving average of GBX 6.45 and a two-hundred day simple moving average of GBX 7.16. The company has a debt-to-equity ratio of 43.38, a quick ratio of 1.16 and a current ratio of 1.21. The firm has a market cap of £40.00 million, a price-to-earnings ratio of -3.26 and a beta of 1.69.
hVIVO (LON:HVO – Get Free Report) last announced its earnings results on Tuesday, September 15th. The company reported GBX (0.82) earnings per share for the quarter. hVIVO had a negative net margin of 31.76% and a negative return on equity of 35.13%. On average, equities analysts forecast that hVIVO will post 1.55 EPS for the current fiscal year.
hVIVO Company Profile
hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model. In addition, the company is developing a database of infectious disease progression data that include Disease in Motion platform, which comprises unique datasets, such as clinical, immunological, virological, and digital (wearable) biomarkers.
Recommended Stories
- Five stocks we like better than hVIVO
- A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?
- Could T-Mobile’s Satellite Competition Fears Create a Buying Opportunity?
- Surgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow Runway
- Tesla’s Robotaxi Lands in Paris—But Europe’s Real Fight Is Over Cheap EVs
Receive News & Ratings for hVIVO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for hVIVO and related companies with MarketBeat.com's FREE daily email newsletter.
